PepGen Stock (NASDAQ:PEPG)
Previous Close
$4.47
52W Range
$4.00 - $19.30
50D Avg
$7.93
200D Avg
$12.32
Market Cap
$143.42M
Avg Vol (3M)
$106.03K
Beta
1.76
Div Yield
-
PEPG Company Profile
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PEPG Performance
Peer Comparison
| Ticker | Company |
|---|---|
| VIGL | Vigil Neuroscience, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| PRTC | PureTech Health plc |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| RLYB | Rallybio Corporation |
| TYRA | Tyra Biosciences, Inc. |
| TRDA | Entrada Therapeutics, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| PHVS | Pharvaris N.V. |
| MOLN | Molecular Partners AG |
| CMPX | Compass Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |